[Clinical trial of isaxonine in diabetic neuropathies (author's transl)].
A double-blind survey of isaxonine versus a placebo was carried out with two groups of diabetics on clinical and electrophysiological evidence of nervous system impairment. The active agent showed a particularly favourable effect on sensory disorders (paresthesia, pain, perception sensibility). The clinical results were correlated with the electrophysiological results (electromyograms, motor nerve conduction velocity). Even with a well-balanced glycemic regulation, which was taken into account for each case but which is not sufficient to rule out the development of neuropathy, improvements shown by patients treated with isaxonine were more numerous and of better quality.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*
D011743:Pyrimidines; C020375:isaxonine
Essai clinique de l'isaxonine dans les neuropathies diabétiques.